Table 2.

Plating efficiencies of BRG1-deficient and -proficient NSCLC cell lines and human fibroblast lines after exposure to lipofectamine, control siRNA, and BRM siRNA

Cell lineBRG1 mutationClassification ATCCPlating efficiency of lipofectamine-exposed control cellsPlating efficiency of control siRNA-transfected cellsPlating efficiency of BRM siRNA-transfected cells
H1299YesAdenocarcinoma0.36 (0.30–0.44)0.37 (0.30–0.45)0.20 (0.16–0.24)***
A549YesAdenocarcinoma0.58 (0.43–0.80)0.63 (0.45–0.88)0.16 (0.12–0.22)***
H661YesLarge cell carcinoma0.26 (0.18–0.38)0.079 (0.046–0.133)‡‡‡0.085 (0.060–0.121)
H661YesLarge cell carcinoma0.32 (0.22–0.46)0.138 (0.097–0.196)‡ Control shRNA0.087 (0.063–0.123) BRM shRNA
HCC15YesSquamous cell carcinoma0.30 (0.21–0.35)0.29 (0.23–0.37)0.11 (0.08–0.14)***
HCC827NoAdenocarcinoma0.23 (0.18–0.29)0.16 (0.13–0.21)‡0.19 (0.15–0.24)
H520NoSquamous cell carcinoma0.17 (0.11–0.28)0.14 (0.09–0.22)0.15 (0.09–0.24)
H596NoAdeno squamous carcinoma0.13 (0.08–0.22)0.13 (0.08–0.22)0.12 (0.08–0.21)
H460NoLarge cell carcinoma0.54 (0.42–0.68)0.50 (0.38–0.63)0.50 (0.39–0.63)
HDFANoAdult fibroblasts0.047 (0.030–0.075)0.046 (0.029–0.073)0.036 (0.022–0.057)
HDFNNoNeonatal fibroblasts0.091 (0.084–0.097)0.090 (0.084–0.097)0.087 (0.081–0.093)
  • NOTE: Asterisks indicate significant differences between siBRM- and siControl-treated cells, as determined by the F-test.

  • *, P < 0.05; **, P < 0.01; ***, P < 0.001.

  • ‡Symbols indicate significant differences between lipofectamine and siControl/shControl-treated cells, as determined by the F-test.

  • ‡, P < 0.05; ‡‡, P < 0.01; ‡‡‡, P < 0.001.